{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:34:09Z","timestamp":1793295249491,"version":"4.5.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"21","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed\/refractory (R\/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is approved for patients with MCL who have received \u22651 prior therapy. We report the long-term safety and efficacy results from the multicenter, open-label, phase 2 registration trial of zanubrutinib. Patients (n = 86) received oral zanubrutinib 160 mg twice daily. The primary endpoint was the overall response rate (ORR), assessed per Lugano 2014. After a median follow-up of 35.3 months, the ORR was 83.7%, with 77.9% achieving complete response (CR); the median duration of response was not reached. Median progression-free survival (PFS) was 33.0 months (95% confidence interval [CI], 19.4-NE). The 36-month PFS and overall survival (OS) rates were 47.6% (95% CI, 36.2-58.1) and 74.8% (95% CI, 63.7-83.0), respectively. The safety profile was largely unchanged with extended follow-up. Most common (\u226520%) all-grade adverse events (AEs) were neutrophil count decreased (46.5%), upper respiratory tract infection (38.4%), rash (36.0%), white blood cell count decreased (33.7%), and platelet count decreased (32.6%); most were grade 1\/2 events. Most common (\u226510%) grade \u22653 AEs were neutrophil count decreased (18.6%) and pneumonia (12.8%). Rates of infection, neutropenia, and bleeding were highest in the first 6 months of therapy and decreased thereafter. No cases of atrial fibrillation\/flutter, grade \u22653 cardiac AEs, second primary malignancies, or tumor lysis syndrome were reported. After extended follow-up, zanubrutinib demonstrated durable responses and a favorable safety profile in R\/R MCL. The trial is registered at ClinicalTrials.gov as NCT03206970.<\/jats:p>","DOI":"10.1182\/blood.2021014162","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T19:59:21Z","timestamp":1647633561000},"page":"3148-3158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":167,"title":["Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study"],"prefix":"10.1182","volume":"139","author":[{"given":"Yuqin","family":"Song","sequence":"first","affiliation":[{"name":"1Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-1377","authenticated-orcid":false,"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"3State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[{"name":"5Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"7Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[{"name":"8Department of Hematology, West China Hospital of Sichuan University, Chengdu, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"9Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"10Department of Hematology, the First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[{"name":"11Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyi","family":"Guo","sequence":"additional","affiliation":[{"name":"14BeiGene (Shanghai) Co., Ltd., Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[{"name":"15BeiGene (Beijing) Co., Ltd., Beijing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Huang","sequence":"additional","affiliation":[{"name":"16BeiGene USA, Inc., San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Novotny","sequence":"additional","affiliation":[{"name":"16BeiGene USA, Inc., San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil","family":"Kim","sequence":"additional","affiliation":[{"name":"16BeiGene USA, Inc., San Mateo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Yu","sequence":"additional","affiliation":[{"name":"14BeiGene (Shanghai) Co., Ltd., Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghao","family":"Wu","sequence":"additional","affiliation":[{"name":"14BeiGene (Shanghai) Co., Ltd., Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2022052615231251000_B1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"issue":"6","key":"2022052615231251000_B2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3390\/jcm10061207","article-title":"Relapsed mantle cell lymphoma: current management, recent progress, and future directions","volume":"10","author":"Bond","year":"2021","journal-title":"J Clin Med."},{"issue":"9","key":"2022052615231251000_B3","first-page":"11","article-title":"Mantle cell lymphoma: the changing landscape","volume":"11(suppl 14, pt","author":"Goy","year":"2013","journal-title":"Clin Adv Hematol Oncol."},{"issue":"1","key":"2022052615231251000_B4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.13101","article-title":"Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma","volume":"168","author":"Furtado","year":"2015","journal-title":"Br J Haematol."},{"issue":"12","key":"2022052615231251000_B5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022052615231251000_B6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol."},{"issue":"6","key":"2022052615231251000_B7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood."},{"issue":"12","key":"2022052615231251000_B8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood."},{"issue":"2","key":"2022052615231251000_B9","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr Oncol."},{"key":"2022052615231251000_B10"},{"key":"2022052615231251000_B11"},{"key":"2022052615231251000_B12"},{"issue":"6","key":"2022052615231251000_B13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med."},{"issue":"10020","key":"2022052615231251000_B14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet."},{"issue":"10","key":"2022052615231251000_B15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica."},{"issue":"5","key":"2022052615231251000_B16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica."},{"issue":"1","key":"2022052615231251000_B17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"issue":"20","key":"2022052615231251000_B18","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv."},{"issue":"10121","key":"2022052615231251000_B19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet."},{"key":"2022052615231251000_B20","author":"Wang"},{"issue":"17","key":"2022052615231251000_B21","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem."},{"issue":"11","key":"2022052615231251000_B22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood."},{"issue":"18","key":"2022052615231251000_B23","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood."},{"key":"2022052615231251000_B24","author":"Hillmen"},{"issue":"16","key":"2022052615231251000_B25","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"27","key":"2022052615231251000_B26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022052615231251000_B27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics."},{"issue":"282","key":"2022052615231251000_B28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2022052615231251000_B29","first-page":"1","volume-title":"Rep Public Health MedSub.","author":"Greenwood","year":"1926"},{"issue":"5","key":"2022052615231251000_B30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/joim.12633","article-title":"Genetic landscape and deregulated pathways in B-cell lymphoid malignancies","volume":"282","author":"Rosenquist","year":"2017","journal-title":"J Intern Med."},{"issue":"12","key":"2022052615231251000_B31","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"2022052615231251000_B32","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica."},{"issue":"13","key":"2022052615231251000_B33","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"2022052615231251000_B34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"2022052615231251000_B35","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol."},{"issue":"21","key":"2022052615231251000_B36","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V124.21.3118.3118","article-title":"Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-cell mediated cytotoxicity","volume":"124","author":"Rajasekaran","year":"2014","journal-title":"Blood."},{"issue":"2","key":"2022052615231251000_B37","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica."},{"issue":"3","key":"2022052615231251000_B38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/fon-2020-0794","article-title":"A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma","volume":"17","author":"Dreyling","year":"2021","journal-title":"Future Oncol."},{"issue":"9","key":"2022052615231251000_B39","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood."},{"issue":"3","key":"2022052615231251000_B40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/cancers12030642","article-title":"Precision medicine management of chronic lymphocytic leukemia","volume":"12","author":"Moia","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"4","key":"2022052615231251000_B41","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2008-02-139725","article-title":"Constitutively activated notch signaling is involved in survival and apoptosis resistance of B-CLL cells","volume":"113","author":"Rosati","year":"2009","journal-title":"Blood."},{"key":"2022052615231251000_B42","first-page":"261","article-title":"Apoptosis resistance and NOTCH1 mutations impair clinical outcome in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib","volume":"130","author":"Del Poeta","year":"2017","journal-title":"Blood."},{"key":"2022052615231251000_B43","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.1200\/JCO.2016.34.15_suppl.7570","article-title":"Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial","volume":"34","author":"Lenz","year":"2016","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022052615231251000_B44","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood."},{"issue":"18","key":"2022052615231251000_B45","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022052615231251000_B46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2022052615231251000_B47","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"issue":"19","key":"2022052615231251000_B48","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood."},{"issue":"12","key":"2022052615231251000_B49","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","journal-title":"Haematologica."},{"issue":"4","key":"2022052615231251000_B50","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol."},{"key":"2022052615231251000_B51","first-page":"4326","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","volume":"130","author":"Byrd","year":"2017","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/21\/3148\/1898575\/bloodbld2021014162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/21\/3148\/1898575\/bloodbld2021014162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T15:26:28Z","timestamp":1653578788000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/21\/3148\/484435\/Zanubrutinib-in-relapsed-refractory-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":51,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014162","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}